Compare ICON & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICON | HCWB |
|---|---|---|
| Founded | 2023 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.9M |
| IPO Year | N/A | 2021 |
| Metric | ICON | HCWB |
|---|---|---|
| Price | $1.07 | $0.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $22.50 | ★ $35.00 |
| AVG Volume (30 Days) | 131.4K | ★ 431.0K |
| Earning Date | 02-24-2026 | 05-14-2026 |
| Dividend Yield | ★ 4653.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | $22.33 | N/A |
| Revenue Next Year | $23.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.25 |
| 52 Week High | $4.23 | $17.80 |
| Indicator | ICON | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 42.18 |
| Support Level | $0.69 | $0.25 |
| Resistance Level | $1.24 | $0.78 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 35.08 | 57.16 |
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.